Sana Biotechnology Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019 - 2018
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019 - 2018
Selling, General & Admin	64.04	73.3	67.06	50.41	28.27	Upgrade
Research & Development	207.43	253.6	204.37	274.66	232.09	Upgrade
Operating Expenses	271.47	326.9	271.43	325.07	260.36	Upgrade
Operating Income	-271.47	-326.9	-271.43	-325.07	-260.36	Upgrade
Interest & Investment Income	10.47	9.94	3.76	0.68	0.75	Upgrade
Other Non Operating Income (Expenses)	-	-0.05	-0.67	0.31	0.1	Upgrade
EBT Excluding Unusual Items	-261	-317.01	-268.34	-324.09	-259.51	Upgrade
Asset Writedown	-6.4	-7.01	-4.5	-	-	Upgrade
Other Unusual Items	0.64	40.77	3.36	-31.84	-25.79	Upgrade
Pretax Income	-266.76	-283.26	-269.48	-355.93	-285.31	Upgrade
Net Income	-266.76	-283.26	-269.48	-355.93	-285.31	Upgrade
Net Income to Common	-266.76	-283.26	-269.48	-355.93	-285.31	Upgrade
Shares Outstanding (Basic)	231	195	188	166	13	Upgrade
Shares Outstanding (Diluted)	231	195	188	166	13	Upgrade
Shares Change (YoY)	18.68%	3.29%	13.16%	1178.88%	165.43%	Upgrade
EPS (Basic)	-1.16	-1.46	-1.43	-2.14	-21.92	Upgrade
EPS (Diluted)	-1.16	-1.46	-1.43	-2.14	-21.92	Upgrade
Free Cash Flow	-256.58	-273.61	-310.93	-280.92	-161.85	Upgrade
Free Cash Flow Per Share	-1.11	-1.41	-1.65	-1.69	-12.44	Upgrade
EBITDA	-255.97	-309.36	-255.8	-314	-254.44	Upgrade
D&A For EBITDA	15.5	17.54	15.63	11.07	5.92	Upgrade
EBIT	-271.47	-326.9	-271.43	-325.07	-260.36	Upgrade

Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q